X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-11-16 | ANRO | Alto Neuroscience, Inc. | Hanley Jr. Michael Conick | COO | S - Sale+OE | $27.61 | -75,000 | 0 | -100% | -$2,070,389 | |||||
| D | 2026-11-16 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $53.53 | -7,500 | 282,710 | -3% | -$401,460 | |||||
2026-11-16 | SEPN | Septerna, Inc. | Labrucherie Gil M | CFO | S - Sale | $41.62 | -20,000 | 27,002 | -43% | -$832,359 | ||||||
2026-11-18 | BIVI | Biovie Inc. | Do Cuong V | Pres, CEO | P - Purchase | $1.00 | +2,500 | 21,117 | +13% | +$2,493 | ||||||
| D | 2026-11-17 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $51.78 | -3,500 | 153,902 | -2% | -$181,227 | |||||
| M | 2026-11-16 | ANAB | Anaptysbio, Inc | Ecor1 Capital, LLC | Dir, 10% | P - Purchase | $45.98 | +374,580 | 8,254,674 | +5% | +$17,224,593 | |||||
2026-11-17 | CYTK | Cytokinetics Inc | Hessekiel Jeffrey | Chief Legal, Admin Officer | S - Sale | $52.62 | -15,106 | 92,837 | -14% | -$794,878 | ||||||
| M | 2026-11-16 | ROIV | Roivant Sciences Ltd. | Manchester Keith S | Dir | S - Sale | $38.75 | -1,381,762 | 19,304,554 | -7% | -$53,536,738 | |||||
| M | 2026-11-16 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Dir | S - Sale | $38.75 | -1,381,762 | 19,304,554 | -7% | -$53,536,738 | |||||
2026-11-16 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale | $45.48 | -854 | 8,139 | -9% | -$38,840 | ||||||
| M | 2026-11-16 | ROIV | Roivant Sciences Ltd. | Qvt Financial LP | Director by Deputization | S - Sale | $38.75 | -1,381,762 | 19,304,554 | -7% | -$53,536,738 | |||||
2026-11-16 | CRMD | Cormedix Inc. | Kaplan Myron | Dir | P - Purchase | $4.88 | +25,000 | 286,487 | +10% | +$122,000 | ||||||
| D | 2026-11-16 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $61.88 | -2,812 | 105,272 | -3% | -$174,013 | |||||
| D | 2026-11-17 | RYTM | Rhythm Pharmaceuticals, Inc. | Jean Christophe | Dir | S - Sale+OE | $109.66 | -10,000 | 11,712 | -46% | -$1,096,550 | |||||
| D | 2026-11-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $580.43 | -9,500 | 668,728 | -1% | -$5,514,046 | |||||
| D | 2026-11-17 | ASND | Ascendis Pharma A/S | Pedersen Anni Lotte Kirstine Sonderbjerg | EVP, Chief Admin Officer | S - Sale+OE | $263.89 | -20,000 | 19,460 | -51% | -$5,277,720 | |||||
2026-11-16 | LRMR | Larimar Therapeutics, Inc. | Clayton Russell | Chief Medical Officer | P - Purchase | $3.01 | +3,322 | 74,765 | +5% | +$9,999 | ||||||
2026-11-16 | VRTX | Vertex Pharmaceuticals Inc / Ma | Thornberry Nancy | Dir | S - Sale | $547.86 | -1,000 | 1,109 | -47% | -$547,860 | ||||||
2026-11-16 | VRTX | Vertex Pharmaceuticals Inc / Ma | Bhatia Sangeeta N. | Dir | S - Sale | $547.86 | -271 | 4,653 | -6% | -$148,470 | ||||||
2026-11-17 | RPRX | Royalty Pharma Plc | Hite Christopher | EVP, COB, Partnering | S - Sale | $68.15 | -100,000 | 200,723 | -33% | -$6,814,710 | ||||||
| M | 2026-11-16 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $68.81 | -257,122 | 50,390 | -84% | -$17,693,642 | |||||
2026-11-16 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $69.50 | -25,000 | 149,361 | -14% | -$1,737,490 | ||||||
| M | 2026-11-16 | REGN | Regeneron Pharmaceuticals, Inc. | Sing George L | Dir | S - Sale | $958.97 | -2,000 | 25,297 | -7% | -$1,917,945 | |||||
| D | 2026-11-16 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $28.16 | -4,728 | 34,573 | -12% | -$133,140 | |||||
2026-11-16 | FLNA | Filana Therapeutics, Inc. | Barry Richard | Pres, CEO | P - Purchase | $0.47 | +440,206 | 1,778,170 | +33% | +$206,897 | ||||||
| D | 2026-11-16 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, EVP, Treasurer | S - Sale+OE | $29.99 | -11,000 | 167,076 | -6% | -$329,890 | |||||
2026-11-16 | FLNA | Filana Therapeutics, Inc. | Schoen Eric | CFO | P - Purchase | $0.42 | +20,000 | 31,500 | +174% | +$8,400 | ||||||
2026-11-16 | REGN | Regeneron Pharmaceuticals, Inc. | McCourt Marion | EVP Commercial | S - Sale | $960.26 | -566 | 10,524 | -5% | -$543,504 | ||||||
2026-11-18 | ALT | Altimmune, Inc. | Menziuso Richard Thomas | Principal Accounting Officer | P - Purchase | $1.42 | +10,000 | 10,000 | New | +$14,187 | ||||||
| D | 2026-11-17 | REGN | Regeneron Pharmaceuticals, Inc. | Murphy Andrew J | Co-Chief Scientific Officer | S - Sale+OE | $957.76 | -5,011 | 51,193 | -9% | -$4,799,336 | |||||
2026-11-16 | FLNA | Filana Therapeutics, Inc. | Cook Robert Christopher | COO,Legal Officer | P - Purchase | $0.46 | +121,575 | 135,300 | +886% | +$55,925 | ||||||
2026-11-16 | KURA | Kura Oncology, Inc. | Doyle Thomas James | SVP, Finance, Accounting | S - Sale | $7.44 | -4,697 | 138,581 | -3% | -$34,946 | ||||||
| M | 2026-11-16 | KURA | Kura Oncology, Inc. | Leoni Mollie | Chief Medical Officer | S - Sale | $7.45 | -41,250 | 99,845 | -29% | -$307,122 | |||||
| M | 2026-11-16 | KURA | Kura Oncology, Inc. | Powl Brian T. | Chief Commercial Officer | S - Sale | $7.45 | -24,450 | 113,265 | -18% | -$182,061 | |||||
2026-11-16 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | GC | S - Sale | $7.44 | -8,601 | 178,401 | -5% | -$63,991 | ||||||
| M | 2026-11-16 | KURA | Kura Oncology, Inc. | Ford Kathleen | COO | S - Sale | $7.45 | -10,710 | 132,276 | -7% | -$79,756 | |||||
2026-11-16 | IRWD | Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | S - Sale | $4.81 | -5,919 | 344,431 | -2% | -$28,470 | ||||||
| D | 2026-11-18 | ZYME | Zymeworks Inc. | Platshon Scott | EVP, Chief Business Officer | S - Sale+OE | $24.95 | -15,292 | 21,745 | -41% | -$381,535 | |||||
2026-11-17 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Dir | P - Purchase | $0.84 | +25,000 | 168,744 | +17% | +$20,950 | ||||||
| M | 2026-11-16 | BOLT | Bolt Biotherapeutics, Inc. | Coastlands Capital LP | 10% | P - Purchase | $5.84 | +53,094 | 515,510 | +11% | +$309,922 | |||||
| M | 2026-11-13 | KTTA | Pasithea Therapeutics Corp. | Coastlands Capital LP | 10% | P - Purchase | $0.48 | +1,667,514 | 5,502,549 | +43% | +$805,944 | |||||
2026-11-16 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale | $124.65 | -2,718 | 81,397 | -3% | -$338,799 | ||||||
| M | 2026-11-13 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.40 | +13,812 | 3,049,379 | 0% | +$33,149 | |||||
2026-11-13 | RCKT | Rocket Pharmaceuticals, Inc. | Shah Gaurav | CEO | S - Sale | $2.25 | -3,020 | 1,459,812 | 0% | -$6,795 | ||||||
2026-11-13 | RCKT | Rocket Pharmaceuticals, Inc. | Wilson Martin | GC | S - Sale | $2.25 | -4,087 | 541,013 | -1% | -$9,196 | ||||||
| D | 2026-11-16 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $92.28 | -2,000 | 0 | -100% | -$184,560 | |||||
| D | 2026-11-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $587.74 | -9,500 | 668,728 | -1% | -$5,583,501 | |||||
2026-11-13 | BBOT | Bridgebio Oncology Therapeutics, Inc. | Cobo Marc | Principal Accounting Officer | S - Sale | $2.37 | -78 | 13,734 | -1% | -$185 | ||||||
2026-11-13 | CORT | Corcept Therapeutics Inc | Wilson James N | Dir | S - Sale | $72.67 | -10,000 | 1,444,543 | -1% | -$726,678 | ||||||
| D | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | Brady Kelly | See Remarks | S - Sale+OE | $1.38 | -85 | 8,775 | -1% | -$117 | |||||
| D | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | See Remarks | S - Sale+OE | $1.38 | -103 | 8,258 | -1% | -$142 | |||||
| D | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | Dir | S - Sale+OE | $1.38 | -287 | 12,936 | -2% | -$396 | |||||
| D | 2026-11-16 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R | See Remarks | S - Sale+OE | $1.38 | -101 | 8,132 | -1% | -$139 | |||||
2026-11-13 | PEPG | Pepgen Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $5.00 | +8,625,000 | 28,689,545 | +43% | +$43,125,000 | ||||||
| M | 2026-11-13 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.00 | +100,000 | 1,632,918 | +7% | +$100,000 | |||||
| M | 2026-11-13 | MAIA | Maia Biotechnology, Inc. | Vitoc Vlad | CEO, 10% | P - Purchase | $1.00 | +100,000 | 1,359,221 | +8% | +$100,000 | |||||
| AM | 2026-11-13 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $7.52 | +200,000 | 1,414,650 | +16% | +$1,504,765 | |||||
2026-11-16 | CATX | Perspective Therapeutics, Inc. | Morich Frank | Dir | P - Purchase | $0.94 | +15,000 | 30,000 | +100% | +$14,046 | ||||||
| M | 2026-11-13 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $7.52 | +200,000 | 1,414,650 | +16% | +$1,504,765 | |||||
2026-11-12 | BLTE | Belite Bio, Inc | Scholl Hendrik Peter | Chief Medical Officer | S - Sale | $165.99 | -2,000 | 12,500 | -14% | -$331,976 | ||||||
| D | 2026-11-12 | SEPN | Septerna, Inc. | Finer Jeffrey | CEO | S - Sale+OE | $43.62 | -18,500 | 833,909 | -2% | -$807,015 | |||||
| D | 2026-11-16 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $100.96 | -7,000 | 31,771 | -18% | -$706,700 | |||||
| D | 2026-11-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $592.42 | -9,500 | 668,728 | -1% | -$5,627,991 | |||||
2026-11-12 | VRTX | Vertex Pharmaceuticals Inc / Ma | Wagner Charles F Jr | EVP, CO, FO | S - Sale | $547.87 | -15,286 | 31,764 | -32% | -$8,374,741 | ||||||
2026-11-13 | BIVI | Biovie Inc. | Do Cuong V | Pres, CEO | P - Purchase | $1.16 | +2,500 | 18,617 | +16% | +$2,906 | ||||||
2026-11-16 | GERN | Geron Corp | Williams Timothy | EVP, GC | P - Purchase | $0.94 | +12,000 | 12,000 | New | +$11,280 | ||||||
2026-11-13 | GERN | Geron Corp | Semerjian Harout | Pres, CEO | P - Purchase | $0.95 | +53,500 | 53,500 | New | +$50,825 | ||||||
2026-11-13 | AUPH | Aurinia Pharmaceuticals Inc. | Robertson Stephen P. | GC | S - Sale | $15.97 | -11,867 | 576,981 | -2% | -$189,516 | ||||||
2026-11-12 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $325.00 | -500 | 42,122 | -1% | -$162,500 | ||||||
| M | 2026-11-04 | CVSI | Cv Sciences, Inc. | Cheever Charlie E III | 10% | P - Purchase | $0.01 | +5,440,926 | 32,089,637 | +20% | +$54,409 | |||||
| D | 2026-11-12 | MRK | Merck & Co., Inc. | Deluca Richard R. | EVP, Pres, Merck Animal Heallt | S - Sale+OE | $148.01 | -58,185 | 114,291 | -34% | -$8,611,875 | |||||
2026-11-12 | LGND | Ligand Pharmaceuticals Inc | Zimmermann Martine | Dir | S - Sale | $318.17 | -2,000 | 1,782 | -53% | -$636,336 | ||||||
2026-11-13 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | CFO | S - Sale | $16.82 | -1,991 | 117,775 | -2% | -$33,489 | ||||||
2026-11-12 | LFVN | Lifevantage Corp | Beindorff Michael A | Dir | S - Sale | $4.89 | -10,000 | 82,709 | -11% | -$48,861 | ||||||
| M | 2026-11-12 | PHIO | Phio Pharmaceuticals Corp. | Deming David H | Dir | P - Purchase | $0.82 | +12,000 | 61,800 | +24% | +$9,823 | |||||
2026-11-12 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.05 | +1,500 | 9,454,036 | 0% | +$81 | ||||||
2026-11-12 | CATX | Perspective Therapeutics, Inc. | Morich Frank | Dir | P - Purchase | $1.00 | +15,000 | 15,000 | New | +$14,957 | ||||||
2026-11-12 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Dir | P - Purchase | $0.84 | +24,898 | 143,744 | +21% | +$20,906 | ||||||
2026-11-12 | CATX | Perspective Therapeutics, Inc. | Woods Lori A | Dir | P - Purchase | $0.84 | +23,750 | 212,017 | +13% | +$20,040 | ||||||
2026-11-13 | ABEO | Abeona Therapeutics Inc. | Charles Faith L. | Dir | P - Purchase | $2.29 | +15,000 | 191,407 | +9% | +$34,349 | ||||||
2026-11-13 | CRMD | Cormedix Inc. | Todisco Joseph | CEO | P - Purchase | $4.89 | +80,000 | 854,749 | +10% | +$391,200 | ||||||
| D | 2026-11-13 | ZYME | Zymeworks Inc. | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $26.07 | -39,741 | 33,756 | -54% | -$1,035,961 | |||||
| D | 2026-11-12 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $104.97 | -10,000 | 14,219 | -41% | -$1,049,658 | |||||
| D | 2026-11-12 | ORKA | Oruka Therapeutics, Inc. | Ball Kristine M | Dir | S - Sale+OE | $104.93 | -18,000 | 0 | -100% | -$1,888,749 | |||||
2026-11-11 | PBYI | Puma Biotechnology, Inc. | Miller Michael Patrick | Dir | S - Sale | $8.10 | -15,000 | 66,000 | -19% | -$121,457 | ||||||
2026-11-11 | SEPN | Septerna, Inc. | Ezekowitz Alan | Dir | S - Sale | $48.09 | -81,820 | 35,600 | -70% | -$3,934,363 | ||||||
| D | 2026-11-11 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $25.00 | -5,000 | 115,743 | -4% | -$125,000 | |||||
| M | 2026-11-11 | CRVS | Corvus Pharmaceuticals, Inc. | Arcara Jeffrey | Chief Business Officer | P - Purchase | $11.22 | +4,500 | 4,500 | New | +$50,475 | |||||
2026-11-10 | ZLAB | Zai Lab Ltd | Gaynor Richard | Dir | P - Purchase | $27.19 | +1,228 | 81,965 | +2% | +$33,389 | ||||||
2026-11-11 | MANE | Veradermics, Inc | Enright Patrick G | Dir | S - Sale | $150.38 | -500,000 | 1,803,474 | -22% | -$75,190,000 | ||||||
2026-11-11 | MANE | Veradermics, Inc | Longitude Capital Partners V, LLC | 10% | S - Sale | $150.38 | -500,000 | 1,803,474 | -22% | -$75,190,000 | ||||||
2026-11-13 | NTHI | Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | CEO, Pres, 10% | P - Purchase | $5.02 | +30,000 | 7,873,140 | 0% | +$150,501 | ||||||
| M | 2026-11-11 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.61 | -66,632 | 121,219 | -35% | -$973,609 | |||||
| D | 2026-11-11 | MIRM | Mirum Pharmaceuticals, Inc. | Brege Laura | Dir | S - Sale+OE | $94.21 | -14,167 | 15,703 | -47% | -$1,334,656 | |||||
| D | 2026-11-12 | JNJ | Johnson & Johnson | Forminard Elizabeth | EVP, GC | S - Sale+OE | $284.39 | -13,072 | 16,994 | -43% | -$3,717,546 | |||||
2026-11-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $70.80 | -500 | 72,924 | -1% | -$35,400 | ||||||
| D | 2026-11-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $593.52 | -9,500 | 668,728 | -1% | -$5,638,445 | |||||
2026-11-11 | ALDX | Aldeyra Therapeutics, Inc. | Alfieri Michael | Principal Financial Officer | P - Purchase | $0.65 | +10,000 | 17,500 | +133% | +$6,500 | ||||||
| D | 2026-11-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $74.07 | -1,500 | 0 | -100% | -$111,105 | |||||
2026-11-13 | ALT | Altimmune, Inc. | Weaver Gregory L | CFO | P - Purchase | $1.62 | +10,000 | 73,005 | +16% | +$16,200 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |